Viral Vector and Plasmid DNA Manufacturing Market Growth, Size, Trends Analysis - By Vector Type, By Workflow, By Application, By End Use, By Disease - Regional Outlook, Competitive Strategies and Segment Forecast to 2034

Description

Viral Vector and Plasmid DNA Manufacturing Market Introduction and Overview

According to SPER Market Research, 'Viral Vector and Plasmid DNA Manufacturing Market Size - By Vector Type, By Workflow, By Application, By End Use, By Disease - Regional Outlook, Competitive Strategies and Segment Forecast to 2034' state that the Global Viral Vector and Plasmid DNA Manufacturing Market is predicted to reach 41.3 billion by 2034 with a CAGR of 20.46%.

Viral vector and plasmid DNA manufacturing are fundamental to gene therapy, vaccine development, and cell-based treatments, enabling the delivery of genetic material into target cells. Viral vectors such as adeno-associated virus (AAV), lentivirus, and adenovirus are widely used in gene transfer, while plasmid DNA plays a crucial role in producing these vectors and mRNA-based therapeutics.

Restraints: The market for plasmid DNA and viral vector manufacturing is facing many obstacles despite its rapid expansion. Accessibility is restricted by high production costs and intricate manufacturing procedures, particularly for smaller biotech businesses. Product approval and commercialization are hampered by regulatory barriers, such as strict safety and efficacy standards. Since differences in batch quality can affect the efficacy of therapy, maintaining consistency and scalability in the manufacture of viral vectors is still crucial.

Scope of the Report:

Report Metric Details

Market size available for years 2021-2034

Base year considered 2024

Forecast period 2025-2034

Segments covered By Vector Type, By Workflow, By Application, By End Use, By Disease.

Regions covered

North America, Latin America, Asia-Pacific, Europe, and Middle East & Africa.

Companies Covered

Audentes Therapeutics, Batavia Biosciences, BioMarin Pharmaceutical, BioNTech IMFS, Catalent Inc., Cobra Biologics, Genezen laboratories, Lonza, Miltenyi Biotec, RegenxBio, Inc.

Viral Vector and Plasmid DNA Manufacturing Market Segmentation:

By Vector Type: Based on the Vector Type, Global Viral Vector and Plasmid DNA Manufacturing Market is segmented as; Adenovirus, Retrovirus, Adeno-Associated Virus (AAV), Lentivirus, Plasmids and Others.

By Workflow: Based on the Workflow, Global Viral Vector and Plasmid DNA Manufacturing Market is segmented as; Upstream Manufacturing and Downstream Manufacturing.

By Application: Based on the Application, Global Viral Vector and Plasmid DNA Manufacturing Market is segmented as; Antisense & RNAi Therapy, Gene Therapy, Cell Therapy, Vaccinology and Research Applications.

By End Use: Based on the End Use, Global Viral Vector and Plasmid DNA Manufacturing Market is segmented as; Pharmaceutical & Biopharmaceutical Companies and Research Institutes.

By Disease: Based on the Disease, Global Viral Vector and Plasmid DNA Manufacturing Market is segmented as; Cancer, Genetic Disorders, Infectious Diseases and Others.

Product Code: HLCA25100

1. Introduction

1.1. Scope of the report
1.2. Market segment analysis

2. Research Methodology

2.1. Research data source
- 2.1.1. Secondary Data
- 2.1.2. Primary Data
- 2.1.3. SPERs internal database
- 2.1.4. Premium insight from KOLs
2.2. Market size estimation
- 2.2.1. Top-down and Bottom-up approach
2.3. Data triangulation

3. Executive Summary

4. Market Dynamics

4.1. Driver, Restraint, Opportunity and Challenges analysis
- 4.1.1. Drivers
- 4.1.2. Restraints
- 4.1.3. Opportunities
- 4.1.4. Challenges

5. Market variable and outlook

5.1. SWOT Analysis
- 5.1.1. Strengths
- 5.1.2. Weaknesses
- 5.1.3. Opportunities
- 5.1.4. Threats
5.2. PESTEL Analysis
- 5.2.1. Political Landscape
- 5.2.2. Economic Landscape
- 5.2.3. Social Landscape
- 5.2.4. Technological Landscape
- 5.2.5. Environmental Landscape
- 5.2.6. Legal Landscape
5.3. PORTERs Five Forces
- 5.3.1. Bargaining power of suppliers
- 5.3.2. Bargaining power of buyers
- 5.3.3. Threat of Substitute
- 5.3.4. Threat of new entrant
- 5.3.5. Competitive rivalry
5.4. Heat Map Analysis

6. Competitive Landscape

6.1. Global Viral Vector and Plasmid DNA Manufacturing Market Manufacturing Base Distribution, Sales Area, Interface Type
6.2. Mergers & Acquisitions, Partnerships, Interface Launch, and Collaboration in Global Viral Vector and Plasmid DNA Manufacturing Market

7. Global Viral Vector and Plasmid DNA Manufacturing Market, By Vector Type 2021-2034 (USD Million)

7.1. Adenovirus
7.2. Retrovirus
7.3. Adeno-Associated Virus (AAV)
7.4. Lentivirus
7.5. Plasmids
7.6. Others

8. Global Viral Vector and Plasmid DNA Manufacturing Market, By Workflow 2021-2034 (USD Million)

8.1. Upstream Manufacturing
- 8.1.1. Vector Amplification & Expansion
- 8.1.2. Vector Recovery/Harvesting
8.2. Downstream Manufacturing
- 8.2.1. Purification
- 8.2.2. Fill Finish

9. Global Viral Vector and Plasmid DNA Manufacturing Market, By Application 2021-2034 (USD Million)

9.1. Antisense & RNAi Therapy
9.2. Gene Therapy
9.3. Cell Therapy
9.4. Vaccinology
9.5. Research Applications

10. Global Viral Vector and Plasmid DNA Manufacturing Market, By End Use 2021-2034 (USD Million)

10.1. Pharmaceutical and Biopharmaceutical Companies
10.2. Research Institutes

11. Global Viral Vector and Plasmid DNA Manufacturing Market, By Disease 2021-2034 (USD Million)

11.1. Cancer
11.2. Genetic Disorders
11.3. Infectious Diseases
11.4. Others

12. Global Viral Vector and Plasmid DNA Manufacturing Market, 2021-2034 (USD Million)

12.1. Global Viral Vector and Plasmid DNA Manufacturing Market Size and Market Share

13. Global Viral Vector and Plasmid DNA Manufacturing Market, By Region, 2021-2034 (USD Million)

13.1. Asia-Pacific
- 13.1.1. Australia
- 13.1.2. China
- 13.1.3. India
- 13.1.4. Japan
- 13.1.5. South Korea
- 13.1.6. Rest of Asia-Pacific
13.2. Europe
- 13.2.1. France
- 13.2.2. Germany
- 13.2.3. Italy
- 13.2.4. Spain
- 13.2.5. United Kingdom
- 13.2.6. Rest of Europe
13.3. Middle East and Africa
- 13.3.1. Kingdom of Saudi Arabia
- 13.3.2. United Arab Emirates
- 13.3.3. Qatar
- 13.3.4. South Africa
- 13.3.5. Egypt
- 13.3.6. Morocco
- 13.3.7. Nigeria
- 13.3.8. Rest of Middle-East and Africa
13.4. North America
- 13.4.1. Canada
- 13.4.2. Mexico
- 13.4.3. United States
13.5. Latin America
- 13.5.1. Argentina
- 13.5.2. Brazil
- 13.5.3. Rest of Latin America

14. Company Profile

14.1. Audentes Therapeutics
- 14.1.1. Company details
- 14.1.2. Financial outlook
- 14.1.3. Interface summary
- 14.1.4. Recent developments
14.2. Batavia Biosciences
- 14.2.1. Company details
- 14.2.2. Financial outlook
- 14.2.3. Interface summary
- 14.2.4. Recent developments
14.3. BioMarin Pharmaceutical
- 14.3.1. Company details
- 14.3.2. Financial outlook
- 14.3.3. Interface summary
- 14.3.4. Recent developments
14.4. BioNTech IMFS
- 14.4.1. Company details
- 14.4.2. Financial outlook
- 14.4.3. Interface summary
- 14.4.4. Recent developments
14.5. Catalent Inc.
- 14.5.1. Company details
- 14.5.2. Financial outlook
- 14.5.3. Interface summary
- 14.5.4. Recent developments
14.6. Cobra Biologics
- 14.6.1. Company details
- 14.6.2. Financial outlook
- 14.6.3. Interface summary
- 14.6.4. Recent developments
14.7. Genezen Laboratories
- 14.7.1. Company details
- 14.7.2. Financial outlook
- 14.7.3. Interface summary
- 14.7.4. Recent developments
14.8. Lonza
- 14.8.1. Company details
- 14.8.2. Financial outlook
- 14.8.3. Interface summary
- 14.8.4. Recent developments
14.9. Miltenyi Biotec
- 14.9.1. Company details
- 14.9.2. Financial outlook
- 14.9.3. Interface summary
- 14.9.4. Recent developments
14.10. RegenxBio Inc.
- 14.10.1. Company details
- 14.10.2. Financial outlook
- 14.10.3. Interface summary
- 14.10.4. Recent developments
14.11. Others